Clinical trial · Interventional
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
NCT02132000CI-TRIAL-00014429unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Patients in Premenopausal | — | UNRESOLVED | — |
| Estrogen and/or Progesterone Receptor Positive | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| toremifene or tamoxifen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- tamoxifen
- description
- tamoxifen,20mg/day
- interventionNames
- Drug: toremifene or tamoxifen
- type
- EXPERIMENTAL
- label
- toremifene
- description
- toremifene,60mg/day
- interventionNames
- Drug: toremifene or tamoxifen
Primary outcomes (2)
- measure
- survival outcomes: disease free survival
- timeFrame
- up to 5 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of Breast cancer * Received standard treatment (chemotherapy, operation, or radiotherapy) * premenopausal * estrogen and/or progesterone receptor positive Exclusion Criteria: * Metastatic tumors * During pregnancy or lactation
References
Publications (0)
Data not yet available
No reference posted for this study.